[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"postoperative-urinary-incontinence\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:postoperative-urinary-incontinence":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":5},"100590389","oxybutynin-er-to-promote-early-continence-recovery-after-robotic-prostatectomy-a-randomized-controlled-trial-100590389",false,"NCT06966778","Oxybutynin ER to Promote Early Continence Recovery After Robotic Prostatectomy: A Randomized Controlled Trial","A Double Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy of Oxybutynin Chloride Extended-Release Tablets to Improve Early Continence Recovery After Robotic Prostatectomy","Inclusion Criteria:\n\n* Diagnosis: Patients with localized prostate cancer who are scheduled to undergo robot-assisted radical prostatectomy (RARP).\n* Age: Participants must be 18 years or older, with no upper age limit.\n* Consent: Participants must provide written informed consent before undergoing any study procedures.\n* Ability to Follow Protocol: Participants must be able to follow the protocol procedures throughout the study.\n\nExclusion Criteria:\n\n* Surgical Complications: Participants who experience surgical complications during or after RARP requiring extraordinary medical or surgical treatment.\n* Other Urinary Conditions: Participants with other diseases causing lower urinary tract symptoms (LUTS) or bladder pain, including:\n* \\- Benign prostatic hyperplasia (BPH), chronic prostatitis, interstitial cystitis, painful bladder syndrome, or urinary tract infection.\n* \\- Overactive bladder or any other condition affecting bladder function.\n* Chronic Medication: Participants with long-term use of medications such as:\n* \\- Alpha-blockers, antimuscarinics, or anticholinergics.\n* Glaucoma: Participants with narrow-angle glaucoma.\n* Urinary Retention: Participants with a history of urinary retention.\n* Gastrointestinal Motility Issues: Participants with severe conditions affecting gastrointestinal motility.\n* Concurrent Medications: Participants who are taking medications that are prohibited by the study protocol (e.g., cholinergic drugs, azole antifungals, smooth muscle relaxants).","MALE","18 Years",{"count":19,"type":20},135,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this double-blind, randomized, placebo-controlled study is to evaluate whether oxybutynin chloride extended-release tablets can improve early continence recovery after robot-assisted radical prostatectomy (RARP) in patients with localized prostate cancer.\n\nThe main questions it aims to answer are:\n\n\\[Does oxybutynin chloride improve continence recovery after RARP compared to a placebo?\\] \\[What are the predictors of continence recovery?\\]\n\nResearchers will compare the treatment group (oxybutynin chloride 10 mg\u002Fday) with the control group (placebo) to assess differences in continence outcomes.\n\nParticipants will:\n\n\\[Take the assigned medication (oxybutynin chloride or placebo) daily for 1-3 months until continence recovery.\\] \\[Complete surveys (e.g., IPSS, IIEF, ICIQ) at several time points post-surgery, including before surgery, 10 days after Foley catheter removal, and up to 12 months.\\] \\[Record any adverse events or concomitant medication use.\\]\n\nSafety and tolerability will be monitored, and statistical analyses will determine the efficacy and predictors of continence. The study adheres to ethical principles, local regulations, and GCP guidelines.",[26,27],"Localized Prostate Cancer","Postoperative Urinary Incontinence",[26,29,30,27,31,32,33,34],"Robot-Assisted Radical Prostatectomy (RARP)","Early Continence Recovery","Oxybutynin Chloride","Extended-Release Tablets","Double-Blind Randomized Study","Placebo-Controlled Trial","RECRUITING","2026-03-12",{"date":38,"type":39},"2026-03-16","ACTUAL",{"date":41,"type":39},"2025-09-15",{"date":43,"type":20},"2028-12-31",{"name":45,"class":46},"National Taiwan University Hospital","OTHER"]